A case of cutaneous T cell lymphoma associated with mild autoimmune disorders were also ruled out. A diagnosis of eosinophilia and rise of IgE levels is reported. A population of CTCL was made and treatment with IFN-␣ was started (9 MU
Introduction peripheral blood smears. Eosinophil count was 842/l and total IgE level 2888 KU/l. A new cutaneous biopsy demonOver the last few years, it has become clear that human T cells strated a dense dermal infiltration by CD4 + CD7 − cells in part can be divided into distinct subsets according to the pattern of lacking TCR␤ expression, whereas a bone marrow biopsy cytokine production: Th1 cells secrete mainly IL-2 and intershowed only moderate eosinophilia. feron-␥, whereas Th2-cells produce IL-4 and IL-5. 1 The enriched CD3
− CD4 + population, obtained by depletion Recently, it has been suggested that cutaneous T cell lymof CD3 + cells from PBMC using magnetic beads, as described phoma (CTCL) represents clonal proliferation of Th2-cells. 2 elsewhere, 4 showed defective response to mitogens activating Moreover, two cases of clonal expansion of CD3 − CD4 + T the cells through crosslinking of membrane receptors (PHA cells, without clinical evidence of lymphoma, secreting Th2-and CD3), but proliferative response, and expression of actitype cytokines have been recently described. 3, 4 We report vation markers such as CD69 and CD25, was partially here a new case of CTCL associated with a population of circulating CD3
− CD4 + cells with a Th2-pattern of cytokine production. Table 1 Immunophenotypical analysis
Marker SV Healthy
Case report controls SV, a 49-year-old female, was admitted to our hospital in
PBL (%)
1992 for erythematous eczema-like plaques involving face, restored using the transmembrane activators PMA + ionoRecently, three patients have been reported in whom promycin (data not shown).
liferation of a CD3 − CD4 + T cell population was associated Unstimulated PBMC and CD3
− CD4 + cells from the patient with a Th2-like pattern of cytokine secretion and with hypersecreted very low levels of IL-4, IL-5, IL-2 and IFN-␥, as did eosinophilia with 3 or without 4, 5 hyper IgE. Although in some PBMC from controls (data not shown). After activation, puriof these cases there was no clinical evidence of lymphoma, fied CD3 −
CD4
+ cells produced higher levels of IL-5 and IL-4 the clonal nature of the proliferation was demonstrated by and lower levels of IFN-␥ compared to the patient's and conmolecular biology studies which showed monoclonal trols' CD3 + CD4 + cells (Figure 1 ). Moreover, high levels of ILrearrangement 3 or deletion of TCRB gene. 4 In three other 5 (94 pg/ml; controls 33 ± 30 pg/ml) and soluble CD30 patients, a lymphoma with CD3 − CD4 + phenotype and (26 U/ml; controls 10 ± 8), believed to be a marker of Th2 cell cutaneous involvement developing after several years of hypactivation, were detected in the patient's serum. ereosinophilia and raised IgE levels was described. [6] [7] [8] the 'classical' pathway of T cell activation. On the other hand, T cell proliferation and Th2-cytokine secretion can be induced in vitro, bypassing the TCR/CD3 complex through direct Discussion stimulation of protein kinase C. 4 As raised levels of Th2-cytokine can be detected in vivo in the sera of these patients, [3] [4] [5] Recent data have led to the hypothesis that CTCL represent the in vivo cytokine secretion in these cases is either spontaneous proliferation of malignant helper T cells with a Th2 production or induced by activation through 'alternative' pathways. pattern; in fact, PBMC from patients with CTCL have a defecThese observations provide new insights in our comprehentive capacity to produce IL-2 and IFN-␥, but can produce sion of the pathogenesis of CTCL, and might have therapeutic increased quantity of IL-4. Moreover, mRNA for Th2-type implications leading to treatment with Th2 antagonist cytokines (IL-4, IL-5, IL-10) has been demonstrated in skin cytokines such as IFN-␣, IFN-␥ and IL-12.
2 lesions from patients with CTCL.
2

Figure 1
Cytokine production after stimulation with PMA (5 ng/ml) + ionomycin (500 ng/ml) for 72 h, as measured by sandwich ELISA commercial kits. Horizontal bars show 1 s.d. Ten healthy individuals with no history of atopic diseases were used as controls. Richter's syndrome. 5 Several steps in the clinical evolution of these diseases are associated with a variety of recurrent chro-BM, bone marrow; LDH, lactate dehydrogenase; NT, not tested; mosome changes and genetic alterations that could prove
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Immunophenotypes of the mononuclear cells in the peripheral essential to the understanding of leukemogenesis. We would blood (*) and bone marrow (**).
like to report a case of B-CLL that developed Burkitt's type ALL in the bone marrow (BM), which corresponded to clonal evolution of CLL cells with the occurrence of a secondary oculomotor and facial nerve palsy. He was treated with both whole brain irradiation and intrathecal methotrexate, cytarat (8;14) , and prolymphocytic transformation in the peripheral blood (PB).
bine, and prednisolone which was followed by improvement of central nervous system leukemia. In December 1994, he A 76-year-old Japanese man was diagnosed in July 1990 as B-CLL Rai stage 0, manifested by a leukocyte count of 19.3 × died of pneumonia, 22 months after transformation although his hematological findings showed chronic phase of CLL. At 10 9 /l with 63% lymphocytes (Table 1) . Lymphocytes in the PB were positive for HLA-DR, CD19, CD20, CD5, CD25 antidiagnosis and transformation, all PB cells showed a normal karyotype. At acute transformation, 13 of 19 BM cells had gens, and chains of immunoglobulin (Ig), but not CD10 or CD2 antigens. Treatment had not been prescribed until karyotypic changes consisting of t(8;14)(q24;q32) together with trisomy 17 and 3q+. May 1991 when the leukocyte counts had increased to 44 × 10 9 /l together with mild anemia and splenomegaly, and then Whether transformation of B-CLL corresponds to clonal evolution of the initial lymphocyte population or to an indethe patient received cyclophosphamide at 50 mg daily. In February 1993, the patient developed low-grade fever. The leukopendent malignancy with the emergence of a second unrelated clone arising in a susceptible host has been controcyte counts increased to 132.2 × 10 9 /l with 61% lymphocytes and 26.5% prolymphocytes (Figure 1a ).The BM aspirate was versial. 1 In our case, almost all MNC in the BM and PB at transformation expressed the same Ig isotypes (), as well as hypercellular with 42.4% lymphocytes and 53.6% blasts. Morphologically, blasts were consistent with those of Burkitt's PBMNC at other times. Furthermore, blasts in the BM also expressed CD5 antigen. Immature B cells from ALL including type leukemia, L3 in FAB classification (Figure 1b) . Only a few same blasts were found in the PB. At this time, more than Burkitt's type are generally negative for CD5 antigen. 6 These phenotypic findings therefore indicate that not only prolym-90% of mononuclear cells (MNC) from PB and BM including prolymphocytes and blasts, respectively, had the same immuphocytes but also blasts are derived from an identical clone of CLL. We found the identical rearrangement of the Ig heavy nophenotypes as the initial CLL cells (Table 1) . Two courses of chemotherapy with aclarubicin, cyclophosphamide, vincrichain joining region (JH) gene in PB and BM MNC at all timepoints, confirming the clonal evolution of the initial CLL cells stine and prednisolone were followed by the chronic phase of CLL in April 1993. The patient received five courses of further ( Figure 2a ). It is well documented that abnormal karyotypes are significhemotherapy with vincristine and prednisolone weekly. In August 1993, he developed meningeal leukemia with right cantly correlated with advanced clinical stage and shortened survival in CLL. 7 In our case, blasts at transformation morphologically resembled those of Burkitt's type ALL and showed t (8;14) , suggesting that evolution of CLL cells occurred in chromosome translocation. 8 It is possible that we could not We thank Dr TH Rabbitts at the Laboratory of Molecular Biology at Cambridge, UK and the Japanese Cancer Research Our case, therefore, indicated that activation of the c-myc gene is closely associated with clonal evolution even in CLL.
Resources Bank (JCRB) for providing DNA probes of human IgJH and c-myc genes, respectively. This work was partly supRecently, a similar case of Burkitt's type ALL supervening on B-CLL was reported in association with t(8;22). 9 In addition, ported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan, a Grant-inanother case of ALL transformation in CLL carrying t(8;12) which involved c-myc and BTG1 genes was presented. 10 Aid for Cancer Research from the Ministry of Health and Welfare of Japan and a grant to NA from the Okukubo Memorial Moreover, blasts from at least two cases of ALL supervening on CLL resembled those of Burkitt's type ALL. 
Pulmonary embolism in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid
TO THE EDITOR firmed by flebography and Doppler study. Pulmonary embolism was confirmed by perfusion scintigraphy. Fibrinolytic Acute promyelocytic leukemia (APL) accounts for about 10-treatment was administered with r-TPA followed by heparin. A week later, new perfusion scintigraphy showed an important 15% of acute myeloid leukemias.
1 APL has been historically characterized by a high rate of early death, particularly from improvement of the perfusion of both lungs. Thromboembolic complications may also occur in patients intracranial bleeding. The hemorrhagic complications have been attributed to a combination of intravascular thrombin treated with ATRA alone or in combination with chemotherapy, as seen in our case, but are very uncommon. It is of generation, excessive fibrinolysis and/or proteolytic activities released from blast cells. 2 A recent approach for induction interest that several cases of thromboembolic events, rarely clinically evident in patients treated with conventional treatment in APL is differentiation therapy with all-trans-retinoic acid (ATRA). Several trials reported complete remission chemotherapy, have been reported in association with ATRA, especially with ATRA-related hyperleukocytosis. [4] [5] [6] [7] The rapid with progressive improvement in the bone marrow over 1 to 3 months and disappearance of the coagulopathy within 1 or correction of the fibrinogenolysis/proteolysis syndrome in APL patients treated with ATRA may generate a hypercoagulable 2 weeks. 3 Thromboembolic complications in patients treated with ATRA are very uncommon and most of them are associastate during the early phase of treatment, predisposing some patients to display thromboembolic complications. 2 It could ted with ATRA-related hyperleukocytosis.
We report on a 32-year-old patient who presented an APL be necessary to establish a preventive heparinotherapy in these patients. TO THE EDITOR an apparently normal chromosome pattern. X-Y FISH was carried out on cytogenetic preparations; a total of 1000 Several techniques have been applied to detect and monitor interphase cells per specimen was scored for every patient. In chimerism after allogeneic bone marrow transplantation (alloorder to determine the confidence limits, the sensitivity and BMT), but none is quite satisfactory. 1 Recently, in sex-misthe specificity of the technique, we followed the approach of matched allo-BMT recipients, it has been demonstrated that Dewald et al. 2 In our study the normal range for XX cells in FISH with sex chromosome probes (X-Y FISH) is a simple, males was fixed up to 0.791 ± 0.013% and that for XY cells quick and very sensitive technique. 2 In fact, X-Y FISH examin females was fixed up to 0.477 ± 0.03%. The mean percentines both proliferating and G 0 cells and provides more accurage of host and recipient cells, calculated for every patient at ate information about the presence and the number of residual three different periods (14-100, 101-365 and Ͻ365 days), host cells in the recipient marrow. Therefore, X-Y FISH and was always corrected for the cut-offs reported above. conventional cytogenetic studies were carried out in 29 acute After the transplant, 16 patients were in CR and 13 relapsed, leukemia patients (19 acute non-lymphocytic leukemia nine in the marrow and four in extramedullary sites. In the (ANLL) and 10 acute lymphoblastic leukemia (ALL), who statistical analysis, these last four patients were considered in received a non-T cell-depleted allo-BMT from an opposite sex CR, as FISH results were obtained only from bone marrow donor in the period September 1994 to October 1996. Data cells. The median follow-up time determined from the last were analyzed as of October 1996. Mean recipient age was FISH and/or cytogenetic study was 262 days (range 42-1715 30 years (range 14-48); 12 patients were females and 17 days) for the 20 cases in CR and 158 days (range 38-332 days) males. At the time of the transplant seven ANLL (one M2, four for the nine bone marrow relapses. Within the first 20 days M3 and two M4) were in complete remission (CR) and 12 post-transplant X-Y FISH was the technique of choice to study (one M0, four M2 and seven M4) were in relapse; four ALL chimerism, being successful in all nine cases examined; chrowere in CR and six, including three Ph1+ ALL, were in relapse. mosome analysis, on the contrary, provided results in 4/9 The conditioning regimen consisted of busulfan 16 mg/kg over cases. Host cell persistence was observed in 24/24 and in the 4 days and CY 60 mg/kg on each of 2 days (BU-CY) in 11 19/23 patients (mean recipient cell percentages were 6.7 and cases, etoposide (VP) 30 mg/kg on day −4, between busulfan 7.3%) studied by X-Y FISH in the first and in the second per-(16 mg/kg) and CY (60 mg/kg on each of 2 days) in eight, CY iod, and in 9/24 and in 5/20 cases examined by cytogenetics and total body irradiation (TBI) 12 GY (total dose) in 10, all in the same periods. Too few cases were evaluable in the third ALL. GVHD prophylaxis was carried out with methotrexate, time-interval. Therefore our results confirm the persistence of cyclosporine or a combination of the two. recipient cells post-transplant independently of disease status Chromosome studies, performed on bone marrow cells, disas already reported by various authors. [1] [2] [3] The host cell perplayed no irregularity in the sex chromosome complement centage detected is in line with that obtained in other series, and identified clonal karyotype rearrangements in 27/29 being comprised between 5 and 33%. 4, 5 This variability in patients. In ANLL a t(8;21), accompanied by trisomy 8, was recipient cell numbers among the different laboratories is detected in two cases, a t(15;17) in four, a t(9;11) in four, an partly due to stromal cell contamination, higher in direct bone inv(16) with additional rearrangements in two, and a t(3;21) marrow smears than in conventional cytogenetic preparations in three. With regard to ALL, three cases showed the Ph1 chro-(3% vs less than 1%). 1 The presence of stromal cells is probmosome, two hyperdiploidy, two other abnormalities and two ably the reason why X-Y FISH does not foretell relapse but merely defines it. In our study we applied linear regression to correlate variation in host cell percentage with time and with and in relapse. We observed that FISH host cell percentages were significantly associated wtih relapse (P = 0.001), also in developed an abdominal lymphoadenopathy, the other a leukemic bone marrow infiltration, despite chronic GVHD. patients examined in the first and second period (P = 0.01, Relapse also occurred in a patient with hyperdiploidy. There-P = 0.0008). An identical correlation was seen between cytofore in ALL cases, the Ph1 always defined a bad prognosis, genetic results obtained in the second period in cases in CR even if chronic GVHD occurs. and those in relapse (P = 0.007 cases, all transplanted with active disease, relapsed. One
Secondary leukemia after autologous peripheral blood progenitor cell transplantation for breast cancer
TO THE EDITOR dence of secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS) after treatment with doxorubicin and cyclophosphamide. 3 Moreover, there are few reports of Adjuvant chemotherapy for breast cancer has been widely used as routine practice and benefits derived from this acute leukemia and MDS after autologous transplantation primarily for breast cancer 4 or other solid tumours. 5, 6 We approach have been clearly recognized. 1 In the past few years high-dose chemotherapy followed by hemopoietic stem cell recently observed a 38-year-old white female who developed infiltrating lobular carcinoma of the right breast in 1993. At infusion for breast cancer has also been employed and the number of patients receiving this approach is rapidly increasthat time right quadrantectomy was performed. Eleven out of 19 lymph nodes contained metastases and estrogen and proing. 2 Recently some concerns have been raised about the incigesterone receptors were positive. One month later chemotherapy with fluorouracil, epi-doxorubicin and cyclophosphamide (FEC) was initiated. Drug dosages in the first cycle doxorubicin 120 mg/m 2 and fluorouracil 1000 mg/m 2 . G-CSF 5 g/kg was administered after the end of chemotherapy in and treatment options include combination chemotherapy but for some of these patients the therapeutic window is extremely order to mobilize and collect peripheral blood progenitor cells (PBPC). The patient then received three standard cycles of narrow since they have already reached the maximum cumulative dose of anthracyclines and have already been exposed FEC. High-dose chemotherapy with carboplatin 1200 mg/m 2 , etoposide 900 mg/m 2 and melphalan 100 mg/m 2 was perforto high-dose cyclophosphamide or melphalan. Therefore, FLAG chemotherapy could be particularly indicated in sAML med in October 1993 followed by PBPC reinfusion. In October 1996 a mild leukopenia and thrombocytopenia was and excellent results in this setting have already been reported. 16 The question whether high-dose chemotherapy observed. Three months later the patient was referred to our Division of Hematology. Pancytopenia and the presence of per se or cumulative exposure to leukemogenic drugs is responsible for sAML/MDS is as yet unanswered. blast cells in peripheral blood was evident at this time. Fms-like tyrosine kinase 3 (flt3), a member of class III receptor tyrosine kinase, is expressed in the majority of patients with B-lineage acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). 1,2 In a study on the incidence and distribution of the expression of the flt3 gene by amplifying its juxtatransmembrane domain, we found the internal tandem duplication of this region in approximately 17% (5/30) of AML patients. 3 This length mutation was not found in ALL (0/50) and was preferentially seen in AML with monocytic proliferation. We examined 38 samples from 24 patients with chronic myeloid leukemia (CML) for the flt3 expression and the internal tandem duplication. Nineteen samples from 17 patients and 19 samples from 11 patients were obtained at chronic phase (CP) and at blastic crisis (BC), respectively. Among 11 patients with BC, seven showed myelocytic proliferation, two monocytic, one lymphocytic, and one megakaryocytic. PCR with two sets of primers, one for the flanking juxtatransmembrane domain of flt3 and the other for ␤-actin, was performed in one tube after the synthesis of cDNA. In chronic phase, flt3 mRNA was not expressed in 13 out of 19 samples (68%). Hyperexpression of flt3 mRNA was detected in 14 out of 19 samples (74%) from eight patients in BC. Five sequential samples from a patient (case 23) with megakaryocytic BC showed no expression of flt3 mRNA. All four patients (cases 14, 16, 18 and 20) on whom sequential analysis at both CP and BC was performed, showed increased expression of flt3 mRNA in BC. All 20 amplified products exhibiting visible bands were in the same size and no length mutation was detected even in two BC patients who showed monocytic proliferation (Figure 1) . Although the number of cases in the present study is rather limited, our findings indicated that the internal tandem duplication of the flt3 might not be involved in the transformation into BC in CML patients.
Figure 1
Thirty-eight cDNAs from 24 patients with CML and one from a healthy individual were co-amplified in one tube by two setsTwo Burkitt-type lymphoma/leukemia-derived cell lines presenting 3q27 translocations and immunoglobulin/BCL6 chimeric transcripts TO THE EDITOR the J 3 sequence, and with 14q32 chromosomal breakpoint within the area between JH and S ( Figure 1 ). 3q27 translocations, affecting the BCL6 gene, are recognized Next, we constructed cDNA libraries from MD901 and MD903 cells and isolated clones, in which the BCL6 exon 1 as common specific chromosomal abnormalities in B cell non-Hodgkin's lymphomas. [1] [2] [3] [4] [5] [6] We established two Burkitt cell was substituted by sequences from J 2 -C 2 intron within the Ig gene (MD901) or JH sequences within the IgH gene lines carrying 3q27 translocations besides the Burkitt-specific 8q24 translocations, and analyzed the structural alterations of (MD903). We analyzed the 5′ end structure of these chimeric transcripts using the rapid amplification of cDNA end (RACE) 5′ portion of the BCL6 gene.
The cell lines, designated as MD901 and MD903, were technique, employing primers from the BCL6 exons 3 and 2 as gene-specific primers. The structure of each RACE product derived from a 60-year-old male patient with Burkitt-type lymphoma and a 38-year-old male with L3-type acute lymphois described in Figure 2 . For MD901 cells, two mRNA species (designated as P 1 and blastic leukemia, respectively. Both lines were negative for Epstein-Barr virus. MD901 cells presented the immunopheno-P 2 ) were identified. The overlapping 400 bp Ig parts were transcribed from J 2 -C 2 intron in the antisense direction with type of a mature B cell, expressing surface IgM and . The immunophenotype of MD903 cells was that of a pre-B cell, 78 bp additional sequence at the 3′ portion in P 2 type, and spliced to the BCL6 exon 2 at the cryptic donor-acceptor sites. expressing cytoplasmic chains, but not surface immunoglobulins (Igs).
For MD903 cells, three types of RACE product were obtained The karyotypes of MD901 and MD903 cells were determined as 48,XY, t(3;22)(q27;q11), del(6)(q21q25),t(8;22) (q24;q11), add (14)(q32), +2mar and 47,XY,t(3;14)(q27;q32), +7, t(8;22)(q24;q11), dir ins (13;13)(q22;q14q22),der(19) t(1;19)(q23;q13), respectively. In both lines, Southern blot analysis did not detect rearrangements within the 50 kb area around the c-MYC exons, but Northern blot analysis presented high expresssion of the c-MYC mRNA (data not shown). 3q27 breakpoints were located within the first intron of the BCL6 gene in both lines. In MD901 cells, we have already revealed the juxtaposition of the Ig and the BCL6 genes in head to head manner, with 22q11 breakpoint at the 5′ end of the J 2 exon. 7 We constructed a MD903 genomic library and isolated a recombinant clone, containing the reciprocal der(3) junctions with breakpoints in the IgH and the BCL6 genes. The der(3) chromosome carried the IgH locus with rearranged D-J region, in which the D A4 sequence was recombinated to It usually occurs as a complication in the course of acute myeloid leukemia (AML), and occasionally in tology of the breast tumor showed that the cells infiltrating the breast tissue were identical to those from bone marrow biopsy chronic myeloid leukemia (CML) or other myeloproliferative disorders (MPD). Isolated chloromas had been described rela- (Figure 1a ) and were positive for lysozyme and myeloperoxidase (Figure 1b) . These findings indicated that the original tively rarely. They may occur in various sites, however their presentation in breast is very uncommon and may be misdiagtumor of the breast was an isolated chloroma, which preceded the acute myelogenous leukemia. The breast tissue examined nosed, mainly as lymphoma. 1 As most of the cases invariably progress to AML, standard induction chemotherapy for AML is by FISH technique for chromosome 8 did not demonstrate trisomy 8. The patient was treated with fludarabine phosphate recommended at the time of diagnosis. 2 Several chromosomal abnormalities were reported in patients with chloroma. They and high-dose cytarabine 3 and achieved complete remission (CR). After an additional course of consolidation treatment were generally associated with bone marrow involvement, with t(8;21)(q22;) and inv(16)(p13;q22) being found most with high-dose cytarabine, she successfully underwent an frequently.
We describe a patient with a tumor of the breast which was diagnosed originally as a large cell immunoblastic lymphoma and was treated with intensive chemotherapy. Nineteen months later she developed AML. Revised histological examination of the original breast tumor confirmed a diagnosis of chloroma. The cytogenetic studies of her bone marrow at the diagnosis of AML showed a combination of two chromosomal abnormalities: trisomy of chromosome 8 and inversion (16) (p13;q22) , in all the metaphases examined.
A 23-year-old female patient was referred to our hospital in January 1994 with a painless mass in her right breast. The surgically removed mass revealed diffuse infiltration by malignant cells, which stained negative for keratine and common leukocytic antigen (CLA), but some of the large cells showed positive staining for B cells. Morphologic features of sclerosis, starry sky and presence of reticulin in the tumor lead to a diagnosis of diffuse large cell immunoblastic lymphoma with sclerosis. Physical examination was normal except for a scar on her right breast. The clinical staging which included complete blood count, kidney and liver tests, CT scan of neck, chest and abdomen, gallium scan, bone marrow aspiration and bone marrow biopsy was normal. The patient was treated with an intensive chemotherapy protocol for high-risk lymphoma, which included doxorubicin. Her follow-up was uneventful.
Nineteen months later she was admitted to the hospital with fever and chills, her hemoglobin was 9 g/dl, WBC count 1.3 × 10 9 /l with absolute neutrophil count 0.176 × 10 9 /l and platelet count 89 × 10 9 /l. Blood smear revealed 56% blast cells with deeply basophilic cytoplasm and nucleoli. Bone marrow aspiration showed 90% immature cells with positive staining for myeloperoxidase. Bone marrow biopsy demonstrated diffuse infiltration by immature cells which stained positive for lysozyme. Flow cytometry of bone marrow cells allogeneic bone marrow transplantation and remained in therapy regimen for AML, which includes cytosine arabinoside significantly improves survival rate in this disease. 3 An CR 22 months after the diagnosis of AML.
Isolated chloroma is defined as an extramedullary focus of early diagnosis in our patient would have affected the initial management of her disease. As a majority of the extramedulnonlymphatic leukemia in the absence of a previous history of AML, MPD or myelodysplastic syndrome and the presence lary myeloid cell tumors can be successfully detected by fixation-resistant monoclonal antibodies such as antimyeloof normal bone marrow. Our patient presented with an isolated chloroma of the breast, which is a very rare form of peroxidase and antilysosyme associated antigen (CD68), these stains should be used in all cases of atypical lymphoid extramedullary leukemia (EML). In a retrospective study of 16 patients with isolated granulocytic sarcoma only one infiltrates, which do not stain with lymphoid monoclonal antibodies. presented with a tumor of the breast 4 and a recent review of 154 cases with extramedullary myeloid tumors described only 10 patients with breast involvement. 1 The typical pathological
